Ophthalmology News and Research RSS Feed - Ophthalmology News and Research

Anti-VEGF therapy benefits in wet AMD not sustained

Anti-VEGF therapy benefits in wet AMD not sustained

Real-world experience of anti-vascular endothelial growth factor therapy for patients with wet age-related macular degeneration suggests that initial improvements in visual acuity are not maintained over time. [More]
Submacular air injection aids tPA haemorrhage displacement

Submacular air injection aids tPA haemorrhage displacement

Submacular air injection with a microneedle is effective at facilitating the displacement of massive submacular haemorrhages dissolved with tissue plasminogen activator in patients with age-related macular degeneration, an interventional case series shows. [More]
Heavy metallic elements influence AMD progression

Heavy metallic elements influence AMD progression

Researchers report associations between age-related macular degeneration and five heavy metallic elements, in findings that highlight the detrimental effects of pollution but the possible benefits of essential elements supplementation. [More]
AMD severity and progression tracks across eyes

AMD severity and progression tracks across eyes

Age-related macular degeneration in one eye tracks the severity of it in the fellow eye at all stages of the disease, findings from the Beaver Dam Eye study show. [More]

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate. [More]
Promising preliminary results for AKB-9778 in diabetic macular oedema

Promising preliminary results for AKB-9778 in diabetic macular oedema

AKB-9778, a small molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase, has a good safety and efficacy profile in patients with diabetic macular oedema, suggests a preliminary dose-escalation study. [More]

Similar diabetic macular oedema outcomes with deferred vs prompt laser therapy

Visual acuity outcomes are comparable in diabetic macular oedema patients who receive laser treatment 24 weeks or more after initiation of ranibizumab injections and those for whom laser therapy is initiated concurrently, show the 5-year results of a US study. [More]

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

Researchers have found three factors that could identify which patients with retinal angiomatous proliferation receiving anti-vascular endothelial growth factor treatment are likely to develop geographic atrophy. [More]
U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

Oraya Therapy was introduced first in the U.K., followed by Switzerland and Germany. The therapy is intended as a one-time, non-invasive treatment that maintains vision with fewer anti-vascular endothelial growth factor (anti-VEGF) injections into the eye... [More]
Cynosure obtains FDA approval to market SculpSure for non-invasive lipolysis treatment

Cynosure obtains FDA approval to market SculpSure for non-invasive lipolysis treatment

Cynosure, Inc. a leader in laser- and light-based aesthetic treatments, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market SculpSure, the world's first hyperthermic laser treatment for non-invasive lipolysis of the flanks. [More]
Lumenis and top urologists to host instructive workshop series at AUA 2015

Lumenis and top urologists to host instructive workshop series at AUA 2015

Lumenis Ltd., the world's largest energy-based medical device company for surgical, ophthalmology, and aesthetic applications announced today that the company will host an educational symposium, in collaboration with nationally distinguished urologists, and an instructive workshop series at the American Urological Association's (AUA) 2015 Annual Meeting, being held in New Orleans, La., from May 15 – 19, 2015. [More]
NIDEK launches MP-3 Microperimeter

NIDEK launches MP-3 Microperimeter

Advances in the functional evaluation of retinal pathology are due to the use of the microperimeter. The MP-3 measures local retinal sensitivity for functional assessment of the retina... [More]
DataMotion continues to experience rapid growth in healthcare industry

DataMotion continues to experience rapid growth in healthcare industry

DataMotion today announced the company continues to experience rapid growth as a leading health information service provider (HISP) of Direct Secure Messaging for electronic health records (EHR) and HIPAA compliant email encryption. A growing number of EHR system vendors, health information exchanges (HIE) and healthcare providers are selecting both DataMotion Direct and DataMotion SecureMail for their interoperability, scalability and rapid deployment capabilities. [More]
Myopia on the rise across Europe, new study finds

Myopia on the rise across Europe, new study finds

Myopia or short-sightedness is becoming more common across Europe, according to a new study led by King's College London. The meta-analysis of findings from 15 studies by the European Eye Epidemiology Consortium found that around a quarter of the European population is short-sighted but it is nearly twice as common in younger people, with almost half (47 per cent) of the group aged between 25 and 29 years affected. [More]
Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Scientists identify gene that causes hereditary hypertension and brachydactyly type E

Individuals with this altered gene have hereditary hypertension (high blood pressure) and at the same time a skeletal malformation called brachydactyly type E, which is characterized by unusually short fingers and toes. The effect on blood pressure is so serious that -- if left untreated -- it most often leads to death before age fifty. [More]
Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Roche today announced that the U.S. Food and Drug Administration has approved the cobas KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumor samples from metastatic colorectal cancer (mCRC) patients and aid clinicians in determining a therapeutic path for them. [More]
Johns Hopkins Ophthalmology professor Bob Massof receives Helen Keller prize

Johns Hopkins Ophthalmology professor Bob Massof receives Helen Keller prize

Bob Massof, Ph.D., of the Wilmer Eye Institute at Johns Hopkins received the 2015 Helen Keller Prize for Vision Research on May 5... [More]
STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. [More]

Emerging methods may help reveal health of individual eye cells

Researchers are studying ways to get a snapshot of all the genetic material that a single retina cell uses to make proteins, revealing the health of that eye cell. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo. [More]
UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial. [More]
Advertisement
Advertisement